Serum steroid metabolome pattern is associated with the response to prednisolone therapy of male patients with IgA nephropathy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0112077" target="_blank" >RIV/00843989:_____/25:E0112077 - isvavai.cz</a>

Alternative codes found

RIV/00098892:_____/25:10159687 RIV/00216208:11110/25:10507923 RIV/61989592:15110/25:73633213 RIV/00023761:_____/25:N0000012 RIV/00064165:_____/25:10507923

Result on the web

<a href="https://doi.org/10.1080/0886022X.2025.2609353" target="_blank" >https://doi.org/10.1080/0886022X.2025.2609353</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/0886022X.2025.2609353" target="_blank" >10.1080/0886022X.2025.2609353</a>

Result language

angličtina

Original language name

Serum steroid metabolome pattern is associated with the response to prednisolone therapy of male patients with IgA nephropathy

Original language description

IgA nephropathy (IgAN) is characterized by the deposition of galactose-deficient IgA1 (Gd-IgA1)-containing immune complexes into kidney mesangium leading to glomerular inflammation and injury. In patients with active IgAN non-responding to renin-angiotensin system blocking drugs (RASBs), corticosteroids (CSs) are recommended. Although CSs reduce significantly serum levels of Gd-IgA1, IgA-containing immune complexes, and proteinuria, their clinical effect in IgAN is variable. Because IgAN patients exhibit abnormal serum concentration of several endogenous steroid metabolites, some of which exhibit immuno-protective/regulating functions, we analyzed serum metabolites which could predict clinical response to CS therapy. This prospective study was performed in 18 male IgAN patients to identify potential biomarkers for personalized CS therapy. Using LC-MS set of 85 steroid metabolites was tested in the sera of IgAN patients before CS therapy initiation to identify those with statistically different level in patients clinically responding and not-responding to CS therapy. Responders were those subjects whose proteinuria decrease below 1 g/day after 6-12 months of CS therapy. Statistical analysis revealed significant and clinically relevant differences in the steroid profile between responders and non-responders. The key and consistent finding across the entire analysis is that non-responder status is associated with globally higher level of almost all analyzed steroids. The response of IgAN patients to CS therapy could be predicted by measuring the serum levels of selected steroid metabolites to receive steroid profile. Observation needs to be confirmed in large cohorts of various ethnic origin to be applicable for routine clinical protocols.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30217 - Urology and nephrology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Renal failure

ISSN

0886-022X

e-ISSN

1525-6049

Volume of the periodical

47

Issue of the periodical within the volume

article 2609353

Country of publishing house

GB - UNITED KINGDOM

Number of pages

11

Pages from-to

1-11

UT code for WoS article

001654586200001

EID of the result in the Scopus database

2-s2.0-105026638627